Physician profile
Peter G Garrett
NPI 1225031719
$4,525.65
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,509 · 2020: $2,758 · 2021: $81.05 · 2022: $111 · 2023: $67.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $67.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $67.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $2,500.00 | 2020 | |
| Elekta, INC. | $296.48 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $208.25 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $196.52 | 2019 | |
| Siemens Medical Solutions USA, INC. | $144.43 | 2019 | |
| Varian Medical Systems, INC. | $107.50 | 2019 | |
| Novartis Pharmaceuticals Corporation | $92.39 | 2019-2021 | |
| Pharmacyclics LLC, An Abbvie Company | $73.84 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $67.85 | 2019 | |
| Eisai INC. | $67.78 | 2019-2020 | |
| Daiichi Sankyo INC. | $67.68 | 2019-2021 | |
| Incyte Corporation | $64.06 | 2019 | |
| Tactile Systems Technology INC | $52.63 | 2019-2023 | Flexitouch Plus, Entre Plus |
| Astellas Pharma US INC | $52.02 | 2019 | |
| Merck Sharp & Dohme LLC | $49.45 | 2019-2020 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Medicine, INC. | $40.95 | 2019-2020 | |
| Clovis Oncology, INC. | $39.74 | 2019-2020 | |
| Gilead Sciences, INC. | $37.46 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $34.59 | 2019 | |
| Genzyme Corporation | $33.53 | 2019 | |
| Tersera Therapeutics LLC | $30.72 | 2019 | |
| Lilly USA, LLC | $27.61 | 2019-2022 | |
| Glaxosmithkline, LLC. | $26.75 | 2021-2022 | |
| Amgen INC. | $16.71 | 2019 | |
| Abbvie INC. | $15.66 | 2019 | |
| Aurobindo Pharma USA, INC. | $15.13 | 2019 | |
| Emd Serono, INC. | $14.70 | 2020 | |
| Fortovia Therapeutics, INC. | $14.35 | 2019 | |
| Mayne Pharma Commercial LLC | $14.34 | 2022 | |
| Puma Biotechnology, INC. | $13.59 | 2019 | |
| Mylan Institutional INC. | $13.26 | 2019 | |
| Alexion Pharmaceuticals, INC. | $12.84 | 2019 | |
| Agios Pharmaceuticals, INC. | $12.68 | 2019 | |
| Kyowa Kirin, INC. | $12.27 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $12.18 | 2019 | |
| Seagen INC. | $11.87 | 2021 | |
| Pfizer INC. | $11.60 | 2020 | |
| Dova Pharmaceuticals | $11.35 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Garrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.